Description: This article discusses the development process and the impact of implementing levelized commission products.

Description: Mortality Table Slope and Future Improvements

Description: This article highlights the interaction between pricing and corporate. There is a move toward principle-based reserving standards in the United States.

Description: Discussion of American Academy of Actuaries Illustrations Work Group. This article deals specifically with the issue of using mortality improvement assumptions in the illustrations prohibited by the Model Illustration Regulation, suspected in some cases because some UL products incorporate low cost of insurance charges in late durations as part of their product design.

Description: Presented at May 1996 Spring Meeting. Speakers from a bank, stockbrokerage and mutual fund company address, for their industry, the nature of customer contact, methods of distribution, investment management capabilities, the need for a level playing field, and potential cross-breeding of various industries.

Description: In this session 31PD of the Palm Desert Spring Meeting panelists discuss current issues relating to joint and second-to-die insurance products, also known as joint survivor or survivorship insurance. From the Record of the Society of Actuaries, Vol. 23, No. 1.

Description: In this session 14 PD of the New Orleans Annual Meeting, the panel, including a member of the SOA Life Experience Committee, provides an update of the work currently being carried out by the SOA, contributions to SOA studies, and the development of the New Valuation Basic Mortality Table. From the Record of the Society of Actuaries, Volume 27, No. 3.

Description: This session from the 2003 SOA Orlando Meeting covers XXX reserves for term insurance and UL from the ceding company and reinsurer standpoint, X-factor classes, the 2001 CSO and securitization and accessing capital markets for solutions for reserves and capital requirments of XXX. From the Record of the Society of Actuaries, Volume 29, No. 3.